Cerus Corp CERS Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.18 down $0.08, 3.54% at close Oct 16
Last close · Previous close $2.26
- Market cap
- $436.80MAt the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.03Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$2.18down $0.08, 3.54%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.26Oct 15
- Volume2.41MOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.03MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.38 to $3.47; now $2.18
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CERS beat the S&P 500 in 1 of 7 periods.
| Period | CERS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CERS: down 13.8% S&P 500: up 1.5% | CERS trailed the S&P 500 by 15.3 percentage points Trailed |
| 3M | CERS: down 32.1% S&P 500: up 1.9% | CERS trailed the S&P 500 by 34.0 percentage points Trailed |
| YTD | CERS: up 5.8% S&P 500: up 12.8% | CERS trailed the S&P 500 by 7.0 percentage points Trailed |
| 1Y | CERS: up 38.0% S&P 500: up 16.8% | CERS beat the S&P 500 by 21.2 percentage points Beat |
| Long term | ||
| 3Y | CERS: up 60.3% S&P 500: up 81.5% +17.0% vs +22.0% a year | CERS trailed the S&P 500 by 21.2 percentage points Trailed |
| 5Y | CERS: down 64.4% S&P 500: up 83.1% −18.7% vs +12.9% a year | CERS trailed the S&P 500 by 147.5 percentage points Trailed |
| 10Y | CERS: down 57.8% S&P 500: up 319.6% −8.3% vs +15.4% a year | CERS trailed the S&P 500 by 377.4 percentage points Trailed |
$10,000 invested in CERS 10 years ago (Oct 14, 2016) would be worth about $4,217 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
CERS beat the S&P 500 in 1 of 7 periods.
| Period | CERS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CERS: down 13.8% S&P 500: up 1.2% | CERS trailed the S&P 500 by 15.0 percentage points Trailed |
| 3M | CERS: down 32.1% S&P 500: up 1.7% | CERS trailed the S&P 500 by 33.8 percentage points Trailed |
| YTD | CERS: up 5.8% S&P 500: up 11.9% | CERS trailed the S&P 500 by 6.1 percentage points Trailed |
| 1Y | CERS: up 38.0% S&P 500: up 15.5% | CERS beat the S&P 500 by 22.5 percentage points Beat |
| Long term | ||
| 3Y | CERS: up 60.3% S&P 500: up 75.0% +17.0% vs +20.5% a year | CERS trailed the S&P 500 by 14.7 percentage points Trailed |
| 5Y | CERS: down 64.4% S&P 500: up 71.2% −18.7% vs +11.4% a year | CERS trailed the S&P 500 by 135.6 percentage points Trailed |
| 10Y | CERS: down 57.8% S&P 500: up 258.1% −8.3% vs +13.6% a year | CERS trailed the S&P 500 by 315.9 percentage points Trailed |
$10,000 invested in CERS 10 years ago (Oct 14, 2016) would be worth about $4,217 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$80.50
Closing high on . Now 97.3% below that record.
Split-adjusted daily closes since Jan 31, 1997.
Stock splits
CERS hasn’t split since its price history begins in 1997.
Valuation
The Oct 16 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$0.03 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 1.8×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 6.2×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 82.8×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - −0.42%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $456.71MAt the Oct 16 close
What it would cost to buy the whole business: the market cap at the Oct 16 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CERS DCF in Excel. Value Cerus with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $248.01Mup 14.6%
- Net income
- −$6.78M
- Diluted EPS
- −$0.03
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $50.66M | −$2.93M | −$0.02 |
| Q4 FY24 (Dec 31, 2024) | $56.75M | −$2.52M | −$0.01 |
| Q1 FY25 (Mar 31, 2025) | $48.85M | −$7.72M | −$0.04 |
| Q2 FY25 (Jun 30, 2025) | $60.13M | −$5.71M | −$0.03 |
| Q3 FY25 (Sep 30, 2025) | $60.24M | −$19.00K | $0.00 |
| Q4 FY25 (Dec 31, 2025) | $64.58M | −$2.18M | −$0.01 |
| Q1 FY26 (Mar 31, 2026) | $59.89M | −$1.64M | −$0.01 |
| Q2 FY26 (Jun 30, 2026) | $63.30M | −$2.94M | −$0.01 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $159.52M | −$54.37M | −$0.32 |
| FY22 (Dec 31, 2022) | $188.32M | −$42.78M | −$0.24 |
| FY23 (Dec 31, 2023) | $186.80M | −$37.49M | −$0.21 |
| FY24 (Dec 31, 2024) | $201.32M | −$20.92M | −$0.11 |
| FY25 (Dec 31, 2025) | $233.80M | −$15.63M | −$0.08 |
Margins
- Gross 57.2%
- Operating −0.7%
- Net −2.7%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$1.83MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$2.42MLast 12 months
- Capital spending$4.25MLast 12 months
- −0.7%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $532.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $56.89MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$76.80MAs of Jun 30, 2026
- Net debt$19.91MAs of Jun 30, 2026
- 1.83As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 1.10As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −10.3%Last 12 months
Over the last 12 months, Cerus lost money: its net loss was 10.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −3.1%Last 12 months
Over the last 12 months, Cerus’s net loss was 3.1% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Cerus Corp
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CERS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CERS stock FAQ
What is CERS stock’s price today?
Cerus (CERS) traded at $2.18 at the close on , down $0.08 (3.54%) from the previous close of $2.26. Over the past 52 weeks it has traded between $1.38 and $3.47.
If you invested $1,000 in CERS 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CERS on would be worth about $422 at the close on , a total return of −57.8%. The same $1,000 would be worth $356 if invested five years ago, $1,380 if invested one year ago, and $312 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Cerus’s market cap?
Cerus’s market capitalization is about $436.8 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $2.18 (how market cap works). Cerus reported 200.37M shares outstanding at the end of its latest quarter ().
What is CERS’s P/E ratio?
CERS’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.03).
How much revenue does Cerus make?
Cerus reported $248.0 million of revenue over the four quarters to , up 14.6% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $63.3 million, up 5.3% from a year earlier.
Is Cerus profitable?
Not over the four quarters to . Cerus reported a net loss of $6.8 million across those four quarters on $248.0 million of revenue.
What are CERS’s earnings per share?
CERS’s diluted earnings per share were −$0.03 over the four quarters to , compared with −$0.10 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.01 per share, against −$0.03 a year earlier (how EPS works).
Does CERS pay a dividend?
Cerus hasn’t paid a dividend in the last twelve months.
What is CERS’s 52-week high and low?
Over the past 52 weeks CERS has traded as low as $1.38 and as high as $3.47. At $2.18 at the close on , it is 37.2% below that high and 58.0% above the low.
What is CERS’s all-time high?
CERS’s highest closing price was $80.50 on , adjusted for stock splits. At $2.18 at the close on , it is 97.3% below that record.
Has CERS stock ever split?
No. CERS hasn’t split since its price history begins in 1997.
How has CERS stock performed?
Including dividends and measured to the close on , CERS has returned +5.8% so far this year and +38.0% over the past year, and −64.4% over five years (−18.7% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Cerus in?
Cerus is in the Healthcare sector and the Medical Devices industry, and is headquartered in California, USA.
What exchange does CERS trade on?
Cerus trades on the Nasdaq under the ticker symbol CERS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.